P. Martin van Hagen MD, PhD

VanHagen51px Head of the Clinical Immunology department

 Email contact: p.m.vanhagen@erasmusmc.nl

 Clinical Immunology Research Group

The Clinical Immunology group performs both basic, translational and clinical research including clinical trials. The research programs are primarily related to pathophysiology including genetics, diagnostics (for instance new imaging techniques and new treatment modalities). We collaborate closely with the Medical Immunology group (Wim Dik, PhD), Autoimmune Disease group (Marjan Versnel, PhD) and Primary Immunodeficiency Disorders (PID) group (Mirjam van der Burg, PhD). At our outpatient clinic we treat around 1800 patients suffering from autoimmune, autoinflammatory and immunodeficiency diseases.

The basic research of the Clinical Immunology focusses on various diseases i.e. fibrotic disorders such as systemic sclerosis, mastocytosis, eye (especially uveitis) related inflammatory diseases (including sarcoidosis, morbus Sjögren, morbus Behçet, ophthalmic Graves’ disease and inflammatory orbital processes) and immunodeficiency diseases. Most of these diseases are part of expertise centres that are recognized by the Dutch University Federation. A special field of interest of the Clinical Immunology Research Group is neuroendocrine-immune interactions in inflammatory diseases.

video_url

Video:

Download video petct.gallium

 

 

 

 

 

 

 

  

  

 

Movie: 68Gallium-DOTATATE-PET scintigraphy helps to detect granulomatous disease and malignancies

Investigations are performed in close collaboration with the departments of Endocrinology, Nuclear Medicine, Paediatrics, Biostatistics, Ophthalmology, Respiratory diseases and the Eye Hospital Rotterdam. The research programs are primarily related to disease pathophysiology including genetics, diagnostics and new treatment modalities.

 

heatmap-n

Figure: gene expression profiles of human RPE cells after co-culturing with a neuropeptide

 Group members

Internists                                                         Research nurse
Martin van Hagen                                              Marianne van der Ent
Jan van Laar
Virgil Dalm                                                        Secretary/data management
Paula van Biezen                                               Judy Poon
Paul van Daele

PhD students                                                  Clinical Fellows
Jasper Kappen                                                 Maud Hermans
Jeroen Bastiaans                                              Faiz Karim
Lieke Kamphuis                                                Maarten Limper
Sita Virakul                                                       Rakesh Bansie
Rina La Distia Nora                                          Kiki van Bilsen
Narissara Suratannon
Kornvalee Meesilpavikkai
Tim Both
Tim van Houwelingen
Marieke Timmermans
Kiki van Bilsen

 Selected Publications

(See for all publications P.M. van Hagen in Pubmed)

Korthagen NM, van Bilsen CE, Swagemakers SM, van de Peppel HJ, Bastiaans J, van der Spek PJ, van Hagen PM, Dik WA.
Retinal pigment epithelial cells display specific transcriptional responses upon TNF-stimulation.
Br J Ophthalmol. 2015;99:700–704.

Kappen J., Medinagomez M, Van Hagen PM, Stolk L, Estradagil J, Rivadeneira F, Uitterlinden AG, Stanford M, Eldad H, Wallace GR, Soylu M, Van Laar J.
Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behçet disease.
PLoS One. 2015 Mar 23;10(3):e0119085.

Both T, Hoorn EJ, Zietse R, van Laar JA, Dalm VS, Brkic A, Versnel MA, van Hagen PM, van Daele PLA.
Prevalence of distal renal tubular acidosis in primary Sjögren's syndrome.
Rheumatology. doi:10.1093/rheumatology/keu401. First published online: October 29, 2014.

Slávka K, Hofland LJ, De Bruijn HS, Ye Y, Achilefu S, van der Wansem K, van der Ploeg-van den Heuvel A, van Koetsveld PM, Brugts MP, van der Lelij AJ, Sterenborg HJ, ten Hagen TL, Robinson DJ, van Hagen PM.
Somatostatin Analogues for Receptor Targeted Photodynamic Therap.
PLoS One. 2014 Aug 11;9(8):e104448.

Virakul S, Dalm VA, Paridaens D, van den Bosch WA, Hirankarn N, van Hagen PM, Dik WA.
The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.
Graefes Arch Clin Exp Ophthalmol. 2014 Jul;252(7):1101-9.

van Hagen PM, Baarsma GS, van Bilsen CE, Kuijpers RW, van Laar JA, van der Ent M, van Daele PL, Veeger NJ, Vingerling JR, Missotten TO.
A noncontrolled trial of anti-TNF-α chimeric monoclonal antibody (infliximab, Remicade® ) in exudative age-related macular degeneration.
Acta Ophthalmol. 2014 Dec;92(8):e691-2.

Tjon SW, van Gent R, van Hagen PM, Mancham S, van der Laan LJ, te Boekhorst PA, Metselaar HJ, Kwekkeboom J.
Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production.
J Immunol. 2014 Jun 15;192(12):5625-34.

Berkowska MA, Heeringa JJ, Hajdarbegovic E, van der Burg M, Thio HB, van Hagen PM, Boon L, Orfao A, van Dongen JJ and van Zelm MC.
Human IgE+ B cells are derived from T cell-dependent and -independent pathways.
J Allergy Clin Immunol. 2014 Sep;134(3):688-697.e6.

Kamphuis LS, Bonte-Mineur F, van Laar JA, van Hagen PM and van Daele PL.
Calcium and vitamin D in sarcoïdosis: is supplementation safe?
J Bone Miner Res. 2014 Nov;29(11):2498-503.

van der Weerd K, van Hagen PM, Schrijver B, Heuvelmans SJ, Hofland L, Swagemakers SMA, Bogers AJ, Dik WA, Visser TJ, van Dongen JJM, van der Lelij AJ and Staal SJ.
Thyroid stimulating hormone acts as a T-cell developmental factor in mice and humans.
Thyroid. 2014 March 18.

Brkic Z, Corneth OB, van Helden-Meeuwsen CC, Dolhain RJ, Maria NI, Paulissen SM, Davelaar N, van Hamburg JP, van Daele PL, Dalm VA, van Hagen PM, Hazes JM, Versnel MA and Lubberts E.
Th17 cytokines and Interferon type I: partners in crime in SLE?
Arthritis Research & Therapy. 2014 March 6;16(2):R62.

La Distia Nora R, van Velthoven ME, Ten Dam-van Loon NH, Misotten T, Bakker M, van Hagen MP, Rothova A.
Clinical Manifestations of Patients with Intraocular Inflammation and Positive QuantiFERON-TB Gold In-Tube Test in a Country Non-endemic for Tuberculosis.
Am J Ophthalmol. 2013 Nov 18. pi: S0002-9394(13)00736-8.

Bastiaans J, van Hagen PM, Dik W.
Thrombin induces epithelial-mesenchymal transition and collagen production by retinal pigment epithelial cells via autocrine PDGF-receptor signaling.
Invest Ophthalmol Vis Sci. 2013 Dec 3.

Van der Weerd K, van Hagen PM, Schrijver B, Kwekkeboom DJ, de Herder WW, ten Broek MR, Postema PT, van Dongen J, Staal FJ, Dik W.
The peripheral blood compartment in patients with Graves’ disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes.
Clinical and Experimental Immunology. Nov 2013;174(2):256-64.

Driessen GJ, Dalm VA , van Hagen PM, Grashoff PA, Hartwig NA, van Rossum A, Warris A, de Vries E, Barendregt BH. Chishimba S, Pico I, Posthumus S, van Zelm MC, van Dongen JJ and van der Burg M.
Common Variable Immunodeficiency and Idiopathic Primary Hypogammaglobulinemia: two different conditions within the same disease spectrum.
Haematologica. Oct 2013;98(10):1617-1623.

Siemiatkowska AM, van den Born LI, van Hagen PM, Stoffels M, Neveling K, Henkes A, Kipping-Geertsema M, Hoefsloot LH, Hoyng CB, Simon A, den Hollander AI, Cremers FP, Collin RW.
Mutations in the Mevalonate Kinase (MVK) Gene Cause Nonsyndromic Retinitis Pigmentosa.
Ophthalmology. 2013 Dec;120(12):2697-705.

Missotten T, Tielemans D, Bromberg JE, van Hagen PM, van Lochem EG, van Dongen JJ, Baarsma GS, Langerak AW.
Multicolor flowcytometric immunophenotyping is a valuable tool for detection of intraocular lymphoma.
Ophthalmology. 2013 May;120(5):991-6.

Dalm VA, van Hagen PM.
Efficacy of lenalidomide in refractory lupus pernio.
JAMA Dermatol. 2013 Apr;149(4):493-4.

Kamphuis, L.S. (Lieke ), Zelm, M.C. van (Menno), Lam, K.H. (King), Rimmelzwaan, G.F. (Guus), Baarsma, G.S. (Seerp), Dik, W.A. (Willem), Thio, H.B. (Bing), Daele, P.L.A., Velthoven, M.E. van (Mirjam ), Batstra, M.R. (Manou), van Hagen, P.M. van (Martin) and van Laar, J.A.M.
Peri-granuloma localization and abnormal maturation of B cells: emerging key players in sarcoidosis?
American Journal of Respiratory and Critical Care Medicine. 2013 Feb 15;187(4):406-16.

Baerveldt EM, Kappen JH, Thio HB, van Laar JA, van Hagen PM, Prens EP.
Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa.
Ann Rheum Dis. 2013 Apr;72(4):626-7.

van der Weerd K, Dik W, Schrijver B, Bogers A, Maat A, van Nederveen F, van Hagen P, van Dongen J, Langerak A, Staal F.
Combined TCRG and TCRA TREC analysis reveals increased peripheral T-lymphocyte but constant intra-thymic proliferative history upon ageing.
Molecular Immunology. 2013 Mar;53(3):302-12.

van Steensel L, Paridaens D, van Meurs M, van Hagen PM, van den Bosch WA, Kuijpers RW, Drexhage HA, Hooijkaas H, Dik WA.
Orbit-Infiltrating Mast Cells, Monocytes, and Macrophages Produce PDGF isoforms that Orchestrate Orbital Fibroblast Activation in Graves’ Ophthalmopathy.
J. Clin endocrinol Metab. 2012 Mar;97(3):E400-8.

van der Weerd K, Dik W, Schrijver B, Schweitzer D, Langerak A, Drexhage H, Kiewiet R, van Aken M, van Huisstede A, van Dongen JJM, van der Lelij AJ, Staal F, van Hagen PM.
Morbid Obese human Subjects have Increased peripheral Blood CD4+ T cells with Skewing toward a Treg- and Th2-dominated phenotype.
Diabetes. 2012 Feb; 61(2):401-8 Epub 2012 Jan 6.

Driessen GJ, van Zelm MC, van Hagen PM, Hartwig NG, Trip M, Warris A, de Vries E, Barendregt BH, Pico I, Hop W, van Dongen JJM, van der Burg M.
B-cell replication history and somatic hypermutation status identify distinct pathophysiological backgrounds in common variable immunodeficiency".
Blood. 2011 Dec; 118(26);6814-23.

Kamphuis LSJ, Lam-Tse WK, Dik WA, van Daele PL, van Biezen P, Kwekkeboom DJ, Kuijpers RW, Hooijkaas H, van Laar JA, Bastiaans J, Baarsma GS, van Hagen PM.
Efficacy of Adalimumab in Chronically Active and Symptomatic Patients with Sarcoidosis.
American Journ of Respiratory and Critical Care Medicine vol. 184 2011 Nov 15;184(10):1214-6.

van Bilsen C, van Hagen PM, Bastiaans J, van Meurs JC, Missotten T, Kuijpers R, Hooijkaas H, Dingjan GM, Baarsma GS, Dik WA.
The Neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumor necrosis factor-alpha.
Br J Ophthalmol. 2011 Jun;95(6):864-8.

Baeten D, van Hagen PM.
Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational?
Ann Rheum Dis. 2010 Aug.

van Steensel L, Paridaens D, Dingjan GM, van Daele PL, van Hagen PM, Kuijpers RW, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA.
Platelet-derived growth factor-BB: A stimulus for cytokine production by orbital firoblasts in Graves’ ophthalmopathy.
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1002-7.

Kappen JH, Wallace GR, Stolk L, Rivadeneira F, Uitterlinden AG, van Daele PL, Laman JD, Kuijpers RW, Baarsma GS, Stanford MR, Fortune F, Madanat W, van Hagen PM van Laar JA.
Low prevalence of NOD2 SNPs in Behcet’s disease suggests protective association in Caucasians. Rheumatology (Oxford). 2009 Nov; 48(11):1375-7.

Aksentijevich I. et al
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.
New England Journal of Medicine. 2009 June 4; 360 (23):2426-37.

van Laar JAM, Kappen JH, van Daele PLA, van Hagen PM.
Do synovial biopsies help to support evidence for involvement of innate immunity in the immunopathology of Behçet’s disease?
Arthritis Research & Therapy. 2009 April; 11:109.

Van Steensel L, Paridaens D, Schrijver B, Dingjan GM, van Daele PLA, van Hagen PM, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik, WA.
Imatinib mesylate and AMN107 are potential drugs for Graves’ Ophthalmopathy by inhibition of PDGF-signaling in orbital fibroblasts.
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3091-8.

Kappen JH, Mensink PB, Lesterhuis W, Lachman S, van Daele PL, van Hagen PM, van Laar JA.
Mycophenolate sodium: effective treatment for therapy-refractory intestinal Behçet's disease, evaluated with enteroscopy.
Am J Gastroenterol. 2008 Dec; 103(12): 3213-4.

van Daele PL, Dik WA, Thio HB, van Hal PT, van Laar JA, Hooijkaas H, van Hagen PM.
Is Imatinib Mesylate a Promising Drug in Systemic Sclerosis?
Arthritis & Rheumatism. 2008 Aug; 58 (8): 2549-52.

Wehr C et al.
The EUROclass trial: Defining subgroups in common variable immunodeficiency.
Blood. 2008 Jan 1;111(1):77-85.

Missotten T, van Laar JAM, van der Loos T, van Daele P, Baarsma GS, van Hagen PM.
Octreotide® Long-Acting Repeatable for the treatment of chronic macular edema in uveitis.
Am J Ophthalmology. 2007; 6: 838-43.

van Laar JAM, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM.
Adalimumab; a new modality for Behcet’s disease?
Ann Rheum Dis. april, 2007; 66(4):565-6.

van Daele PLA, Bakker M, van Hagen PM, Baarsma GS, Kuijpers RWAM.
TB or not TB: treat to see.
Med J Australia. 2006; 185: 178-9.

Paridaens D, van den Bosch WA, van der Loos, TL, Krenning, EP, van Hagen PM.
The effect of etanercept on Graves' ophthalmopathy: a pilot study.
Eye. 2005; 19: 1286-9.

Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM.
Anti-TNF-alpha therapy for sight threatening uveitis.
Br J Ophthalmol. 2005; 89: 533-6.

Hofland LJ, Capello A, Krenning EP, de Jong M, van Hagen PM.
Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides.
J Nucl Med. 2005; 46: 1915-85.

van Noord C, Hooijkaas H, Dufour-van den Goorbergh BC, van Hagen PM, van Daele PL, van de Merwe JP.
Diagnostic value of anti-cyclic citrullinated peptide antibodies to detect rheumatoid arthritis in patients with Sjogren's syndrome.
Ann Rheum Dis. 2005; 64: 160-2.

Capello A, Krenning EP, Bernard BF, Breeman WA, van Hagen PM, de Jong M.
Increased cell death after therapy with an arg-gly-asp-linked somatostatin analog.
J Nucl Med. 2004; 45: 1716-20.

Dalm VA, Hofland LJ, Mooy CM, Waaijers MA, van Koetsveld PM, Langerak AW, Staal FT, van der Lely AJ, Lamberts SW, van Hagen PM.
Somatostatin receptors in malignant lymphomas: targets for radiotherapy?
J Nucl Med. 2004; 45: 8-16.

Dalm VA., van Hagen PM, van Koetsveld PM, Langerak AW, van der Lely AJ, Lamberts SWJ, Hofland LJ.
Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system.
J Clin Endocrinol Metab. 2003; 88: 270-6.

Verjans GM, van Hagen PM, van der Kooi A, Osterhaus AD, Baarsma GS .
Vgamma9Vdelta2 T cells recovered from eyes of patients with Behcet's disease recognize non-peptide prenyl pyrophosphate antigens.
J Neuroimmunol. 2002; 130: 46-54.

Lambooij AC, Kuijpers RW, van Lichtenauer-Kaligis EG, Kliffen M, Baarsma GS, van Hagen PM, Mooy CM.
Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration.
Invest Ophthalmol Vis Sci. 2000; 41: 2329-35.

van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A, Schmidt, MA, Krenning EP, de Jong M.
Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy.
Int J Cancer. 2000 20; 90: 186-98.

Ferone D, van Hagen PM, Kwekkeboom DJ, van Koetsveld PM, Mooy DM, Lichtenauer-Kaligis E, Schonbrunn A, Colao A, Lamberts SWJ, Hofland LJ.
Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro.
J Clin Endocrinol Metab. 2000; 85: 1719-26.

Ten Bokum AM, Hofland LJ, van Hagen PM.
Somatostatin and somatostatin receptors in the immune system.
Eur Cytokine Netw. 2000; 11: 161-76.

Ferone D, van Hagen PM, van Koetsveld PM, Zuijderwijk J, Mooy CM, Lichtenauer-Kaligis EGR, Colao A, Bogers AJJC, Lombardi G, Lamberts SWJ, Hofland LJ.
In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells.
Endocrinology. 1999; 140: 373-80.

Kwekkeboom DJ, Breeman WAP, Krenning EP, van Hagen PM.
Octreotide scintigraphy in sarcoidosis.
Eur J Nucl Med. 1998: 25: 1284-92.

Kuijpers RWAM, Baarsma S, van Hagen PM.
Treatment of cystoid macula edema with octreotide.
N Eng J Med. 1998: 26; 624-6.

Hagen PM van, Breeman WAP, Reubi JC, Postema PTE, Anker-Lugtenburg PJ van den, Kwekkeboom DJ, Laissue J, Waser B, Lamberts SWJ, Visser TJ, Krenning EP.
Visualization of the thymus by substance P receptor scintigraphy in man.
Eur J Nucl Med. 1996; 23: 1508-13.

Jansen A, van Hagen PM, Drexhage HA.
Defective maturation and function of antigen-presenting cells in type 1 diabetes.
Lancet. 1995; 345: 491-492.

Bac DJ, van Hagen PM, Postema PTE, ten Bokum AM, Zondervan PE, Blankenstein M.
Octreotide for protein losing enteropathy with intestinal lymphangiectasia.
Lancet. 1995;345:1639.

Feron EJ, Rothova A, van Hagen PM, Baarsma GS.
Interferon-alpha 2b for refractory ocular Behçet's disease.
Lancet. 1994;343:1428.

van Hagen PM, Krenning EP, Reubi JC, Kwekkeboom DJ, Bakker WH, Mulder AH, Laissue JA, Hoogsteden HC, Lamberts SWJ.
Somatostatin analogue scintigraphy in granulomatous diseases.
Eur J Nucl Med. 1994; 21: 497-502.

Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, van Hagen PM, Koper JW, Lamberts SWJ.
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide in man: metabolism, dosimetry and comparison with [123I-Tyr3]-octreotide.
J Nucl Med. 1992; 33: 652-8.
Korthagen NM, van Bilsen CE, Swagemakers SM, van de Peppel HJ, Bastiaans J, van der Spek PJ, van Hagen PM, Dik WA.
Retinal pigment epithelial cells display specific transcriptional responses upon TNF-stimulation.
Br J Ophthalmol. 2015;99:700–704.

Kappen J., Medinagomez M, Van Hagen PM, Stolk L, Estradagil J, Rivadeneira F, Uitterlinden AG, Stanford M, Eldad H, Wallace GR, Soylu M, Van Laar J.
Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behçet disease.
PLoS One. 2015 Mar 23;10(3):e0119085.

Both T, Hoorn EJ, Zietse R, van Laar JA, Dalm VS, Brkic A, Versnel MA, van Hagen PM, van Daele PLA.
Prevalence of distal renal tubular acidosis in primary Sjögren's syndrome.
Rheumatology. doi:10.1093/rheumatology/keu401. First published online: October 29, 2014.

Slávka K, Hofland LJ, De Bruijn HS, Ye Y, Achilefu S, van der Wansem K, van der Ploeg-van den Heuvel A, van Koetsveld PM, Brugts MP, van der Lelij AJ, Sterenborg HJ, ten Hagen TL, Robinson DJ, van Hagen PM.
Somatostatin Analogues for Receptor Targeted Photodynamic Therap.
PLoS One. 2014 Aug 11;9(8):e104448.

Virakul S, Dalm VA, Paridaens D, van den Bosch WA, Hirankarn N, van Hagen PM, Dik WA.
The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.
Graefes Arch Clin Exp Ophthalmol. 2014 Jul;252(7):1101-9.

van Hagen PM, Baarsma GS, van Bilsen CE, Kuijpers RW, van Laar JA, van der Ent M, van Daele PL, Veeger NJ, Vingerling JR, Missotten TO.
A noncontrolled trial of anti-TNF-a chimeric monoclonal antibody (infliximab, Remicade® ) in exudative age-related macular degeneration.
Acta Ophthalmol. 2014 Dec;92(8):e691-2.

Tjon SW, van Gent R, van Hagen PM, Mancham S, van der Laan LJ, te Boekhorst PA, Metselaar HJ, Kwekkeboom J.
Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production.
J Immunol. 2014 Jun 15;192(12):5625-34.

Berkowska MA, Heeringa JJ, Hajdarbegovic E, van der Burg M, Thio HB, van Hagen PM, Boon L, Orfao A, van Dongen JJ and van Zelm MC.
Human IgE+ B cells are derived from T cell-dependent and -independent pathways.
J Allergy Clin Immunol. 2014 Sep;134(3):688-697.e6.

Kamphuis LS, Bonte-Mineur F, van Laar JA, van Hagen PM and van Daele PL.
Calcium and vitamin D in sarcoïdosis: is supplementation safe?
J Bone Miner Res. 2014 Nov;29(11):2498-503.

van der Weerd K, van Hagen PM, Schrijver B, Heuvelmans SJ, Hofland L, Swagemakers SMA, Bogers AJ, Dik WA, Visser TJ, van Dongen JJM, van der Lelij AJ and Staal SJ.
Thyroid stimulating hormone acts as a T-cell developmental factor in mice and humans.
Thyroid. 2014 March 18.

Brkic Z, Corneth OB, van Helden-Meeuwsen CC, Dolhain RJ, Maria NI, Paulissen SM, Davelaar N, van Hamburg JP, van Daele PL, Dalm VA, van Hagen PM, Hazes JM, Versnel MA and Lubberts E.
Th17 cytokines and Interferon type I: partners in crime in SLE?
Arthritis Research & Therapy. 2014 March 6;16(2):R62.

La Distia Nora R, van Velthoven ME, Ten Dam-van Loon NH, Misotten T, Bakker M, van Hagen MP, Rothova A.
Clinical Manifestations of Patients with Intraocular Inflammation and Positive QuantiFERON-TB Gold In-Tube Test in a Country Non-endemic for Tuberculosis.
Am J Ophthalmol. 2013 Nov 18. pi: S0002-9394(13)00736-8.

Bastiaans J, van Hagen PM, Dik W.
Thrombin induces epithelial-mesenchymal transition and collagen production by retinal pigment epithelial cells via autocrine PDGF-receptor signaling.
Invest Ophthalmol Vis Sci. 2013 Dec 3.

Van der Weerd K, van Hagen PM, Schrijver B, Kwekkeboom DJ, de Herder WW, ten Broek MR, Postema PT, van Dongen J, Staal FJ, Dik W.
The peripheral blood compartment in patients with Graves’ disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes.
Clinical and Experimental Immunology. Nov 2013;174(2):256-64.

Driessen GJ, Dalm VA , van Hagen PM, Grashoff PA, Hartwig NA, van Rossum A, Warris A, de Vries E, Barendregt BH. Chishimba S, Pico I, Posthumus S, van Zelm MC, van Dongen JJ and van der Burg M.
Common Variable Immunodeficiency and Idiopathic Primary Hypogammaglobulinemia: two different conditions within the same disease spectrum.
Haematologica. Oct 2013;98(10):1617-1623.

Siemiatkowska AM, van den Born LI, van Hagen PM, Stoffels M, Neveling K, Henkes A, Kipping-Geertsema M, Hoefsloot LH, Hoyng CB, Simon A, den Hollander AI, Cremers FP, Collin RW.
Mutations in the Mevalonate Kinase (MVK) Gene Cause Nonsyndromic Retinitis Pigmentosa.
Ophthalmology. 2013 Dec;120(12):2697-705.

Missotten T, Tielemans D, Bromberg JE, van Hagen PM, van Lochem EG, van Dongen JJ, Baarsma GS, Langerak AW.
Multicolor flowcytometric immunophenotyping is a valuable tool for detection of intraocular lymphoma.
Ophthalmology. 2013 May;120(5):991-6.

Dalm VA, van Hagen PM.
Efficacy of lenalidomide in refractory lupus pernio.
JAMA Dermatol. 2013 Apr;149(4):493-4.

Kamphuis, L.S. (Lieke ), Zelm, M.C. van (Menno), Lam, K.H. (King), Rimmelzwaan, G.F. (Guus), Baarsma, G.S. (Seerp), Dik, W.A. (Willem), Thio, H.B. (Bing), Daele, P.L.A., Velthoven, M.E. van (Mirjam ), Batstra, M.R. (Manou), van Hagen, P.M. van (Martin) and van Laar, J.A.M.
Peri-granuloma localization and abnormal maturation of B cells: emerging key players in sarcoidosis?
American Journal of Respiratory and Critical Care Medicine. 2013 Feb 15;187(4):406-16.

Baerveldt EM, Kappen JH, Thio HB, van Laar JA, van Hagen PM, Prens EP.
Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa.
Ann Rheum Dis. 2013 Apr;72(4):626-7.

van der Weerd K, Dik W, Schrijver B, Bogers A, Maat A, van Nederveen F, van Hagen P, van Dongen J, Langerak A, Staal F.
Combined TCRG and TCRA TREC analysis reveals increased peripheral T-lymphocyte but constant intra-thymic proliferative history upon ageing.
Molecular Immunology. 2013 Mar;53(3):302-12.

van Steensel L, Paridaens D, van Meurs M, van Hagen PM, van den Bosch WA, Kuijpers RW, Drexhage HA, Hooijkaas H, Dik WA.
Orbit-Infiltrating Mast Cells, Monocytes, and Macrophages Produce PDGF isoforms that Orchestrate Orbital Fibroblast Activation in Graves’ Ophthalmopathy.
J. Clin endocrinol Metab. 2012 Mar;97(3):E400-8.

van der Weerd K, Dik W, Schrijver B, Schweitzer D, Langerak A, Drexhage H, Kiewiet R, van Aken M, van Huisstede A, van Dongen JJM, van der Lelij AJ, Staal F, van Hagen PM.
Morbid Obese human Subjects have Increased peripheral Blood CD4+ T cells with Skewing toward a Treg- and Th2-dominated phenotype.
Diabetes. 2012 Feb; 61(2):401-8 Epub 2012 Jan 6.

Driessen GJ, van Zelm MC, van Hagen PM, Hartwig NG, Trip M, Warris A, de Vries E, Barendregt BH, Pico I, Hop W, van Dongen JJM, van der Burg M.
B-cell replication history and somatic hypermutation status identify distinct pathophysiological backgrounds in common variable immunodeficiency".
Blood. 2011 Dec; 118(26);6814-23.

Kamphuis LSJ, Lam-Tse WK, Dik WA, van Daele PL, van Biezen P, Kwekkeboom DJ, Kuijpers RW, Hooijkaas H, van Laar JA, Bastiaans J, Baarsma GS, van Hagen PM.
Efficacy of Adalimumab in Chronically Active and Symptomatic Patients with Sarcoidosis.
American Journ of Respiratory and Critical Care Medicine vol. 184 2011 Nov 15;184(10):1214-6.

van Bilsen C, van Hagen PM, Bastiaans J, van Meurs JC, Missotten T, Kuijpers R, Hooijkaas H, Dingjan GM, Baarsma GS, Dik WA.
The Neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumor necrosis factor-alpha.
Br J Ophthalmol. 2011 Jun;95(6):864-8.

Baeten D, van Hagen PM.
Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational?
Ann Rheum Dis. 2010 Aug.

van Steensel L, Paridaens D, Dingjan GM, van Daele PL, van Hagen PM, Kuijpers RW, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA.
Platelet-derived growth factor-BB: A stimulus for cytokine production by orbital firoblasts in Graves’ ophthalmopathy.
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1002-7.

Kappen JH, Wallace GR, Stolk L, Rivadeneira F, Uitterlinden AG, van Daele PL, Laman JD, Kuijpers RW, Baarsma GS, Stanford MR, Fortune F, Madanat W, van Hagen PM van Laar JA.
Low prevalence of NOD2 SNPs in Behcet’s disease suggests protective association in Caucasians. Rheumatology (Oxford). 2009 Nov; 48(11):1375-7.

Aksentijevich I. et al
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.
New England Journal of Medicine. 2009 June 4; 360 (23):2426-37.

van Laar JAM, Kappen JH, van Daele PLA, van Hagen PM.
Do synovial biopsies help to support evidence for involvement of innate immunity in the immunopathology of Behçet’s disease?
Arthritis Research & Therapy. 2009 April; 11:109.

Van Steensel L, Paridaens D, Schrijver B, Dingjan GM, van Daele PLA, van Hagen PM, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik, WA.
Imatinib mesylate and AMN107 are potential drugs for Graves’ Ophthalmopathy by inhibition of PDGF-signaling in orbital fibroblasts.
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3091-8.

Kappen JH, Mensink PB, Lesterhuis W, Lachman S, van Daele PL, van Hagen PM, van Laar JA.
Mycophenolate sodium: effective treatment for therapy-refractory intestinal Behçet's disease, evaluated with enteroscopy.
Am J Gastroenterol. 2008 Dec; 103(12): 3213-4.

van Daele PL, Dik WA, Thio HB, van Hal PT, van Laar JA, Hooijkaas H, van Hagen PM.
Is Imatinib Mesylate a Promising Drug in Systemic Sclerosis?
Arthritis & Rheumatism. 2008 Aug; 58 (8): 2549-52.

Wehr C et al.
The EUROclass trial: Defining subgroups in common variable immunodeficiency.
Blood. 2008 Jan 1;111(1):77-85.

Missotten T, van Laar JAM, van der Loos T, van Daele P, Baarsma GS, van Hagen PM.
Octreotide® Long-Acting Repeatable for the treatment of chronic macular edema in uveitis.
Am J Ophthalmology. 2007; 6: 838-43.

van Laar JAM, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM.
Adalimumab; a new modality for Behcet’s disease?
Ann Rheum Dis. april, 2007; 66(4):565-6.

van Daele PLA, Bakker M, van Hagen PM, Baarsma GS, Kuijpers RWAM.
TB or not TB: treat to see.
Med J Australia. 2006; 185: 178-9.

Paridaens D, van den Bosch WA, van der Loos, TL, Krenning, EP, van Hagen PM.
The effect of etanercept on Graves' ophthalmopathy: a pilot study.
Eye. 2005; 19: 1286-9.

Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM.
Anti-TNF-alpha therapy for sight threatening uveitis.
Br J Ophthalmol. 2005; 89: 533-6.

Hofland LJ, Capello A, Krenning EP, de Jong M, van Hagen PM.
Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides.
J Nucl Med. 2005; 46: 1915-85.

van Noord C, Hooijkaas H, Dufour-van den Goorbergh BC, van Hagen PM, van Daele PL, van de Merwe JP.
Diagnostic value of anti-cyclic citrullinated peptide antibodies to detect rheumatoid arthritis in patients with Sjogren's syndrome.
Ann Rheum Dis. 2005; 64: 160-2.

Capello A, Krenning EP, Bernard BF, Breeman WA, van Hagen PM, de Jong M.
Increased cell death after therapy with an arg-gly-asp-linked somatostatin analog.
J Nucl Med. 2004; 45: 1716-20.

Dalm VA, Hofland LJ, Mooy CM, Waaijers MA, van Koetsveld PM, Langerak AW, Staal FT, van der Lely AJ, Lamberts SW, van Hagen PM.
Somatostatin receptors in malignant lymphomas: targets for radiotherapy?
J Nucl Med. 2004; 45: 8-16.

Dalm VA., van Hagen PM, van Koetsveld PM, Langerak AW, van der Lely AJ, Lamberts SWJ, Hofland LJ.
Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system.
J Clin Endocrinol Metab. 2003; 88: 270-6.

Verjans GM, van Hagen PM, van der Kooi A, Osterhaus AD, Baarsma GS .
Vgamma9Vdelta2 T cells recovered from eyes of patients with Behcet's disease recognize non-peptide prenyl pyrophosphate antigens.
J Neuroimmunol. 2002; 130: 46-54.

Lambooij AC, Kuijpers RW, van Lichtenauer-Kaligis EG, Kliffen M, Baarsma GS, van Hagen PM, Mooy CM.
Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration.
Invest Ophthalmol Vis Sci. 2000; 41: 2329-35.

van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A, Schmidt, MA, Krenning EP, de Jong M.
Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy.
Int J Cancer. 2000 20; 90: 186-98.

Ferone D, van Hagen PM, Kwekkeboom DJ, van Koetsveld PM, Mooy DM, Lichtenauer-Kaligis E, Schonbrunn A, Colao A, Lamberts SWJ, Hofland LJ.
Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro.
J Clin Endocrinol Metab. 2000; 85: 1719-26.

Ten Bokum AM, Hofland LJ, van Hagen PM.
Somatostatin and somatostatin receptors in the immune system.
Eur Cytokine Netw. 2000; 11: 161-76.

Ferone D, van Hagen PM, van Koetsveld PM, Zuijderwijk J, Mooy CM, Lichtenauer-Kaligis EGR, Colao A, Bogers AJJC, Lombardi G, Lamberts SWJ, Hofland LJ.
In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells.
Endocrinology. 1999; 140: 373-80.

Kwekkeboom DJ, Breeman WAP, Krenning EP, van Hagen PM.
Octreotide scintigraphy in sarcoidosis.
Eur J Nucl Med. 1998: 25: 1284-92.

Kuijpers RWAM, Baarsma S, van Hagen PM.
Treatment of cystoid macula edema with octreotide.
N Eng J Med. 1998: 26; 624-6.

Hagen PM van, Breeman WAP, Reubi JC, Postema PTE, Anker-Lugtenburg PJ van den, Kwekkeboom DJ, Laissue J, Waser B, Lamberts SWJ, Visser TJ, Krenning EP.
Visualization of the thymus by substance P receptor scintigraphy in man.
Eur J Nucl Med. 1996; 23: 1508-13.

Jansen A, van Hagen PM, Drexhage HA.
Defective maturation and function of antigen-presenting cells in type 1 diabetes.
Lancet. 1995; 345: 491-492.

Bac DJ, van Hagen PM, Postema PTE, ten Bokum AM, Zondervan PE, Blankenstein M.
Octreotide for protein losing enteropathy with intestinal lymphangiectasia.
Lancet. 1995;345:1639.

Feron EJ, Rothova A, van Hagen PM, Baarsma GS.
Interferon-alpha 2b for refractory ocular Behçet's disease.
Lancet. 1994;343:1428.

van Hagen PM, Krenning EP, Reubi JC, Kwekkeboom DJ, Bakker WH, Mulder AH, Laissue JA, Hoogsteden HC, Lamberts SWJ.
Somatostatin analogue scintigraphy in granulomatous diseases.
Eur J Nucl Med. 1994; 21: 497-502.

Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, van Hagen PM, Koper JW, Lamberts SWJ.
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide in man: metabolism, dosimetry and comparison with [123I-Tyr3]-octreotide.
J Nucl Med. 1992; 33: 652-8.